The company is working with a number of pharma companies to aid their drug discovery efforts, including Roche and Lundbeck.

In July 2018, a major deal was also announced with UK pharma major GlaxoSmithKline focusing on R&D of innovative new medicines and potential cures, using human genetics as the basis for discovery. The collboration is worth a $300 million to 23andMe.